5440672026-01-012026-03-315440672026-03-315440672025-03-315440672025-04-012026-03-315440672026-01-012026-03-31in-capmkt:OtherExpenses1Member5440672026-01-012026-03-31in-capmkt:OtherExpenses2Member5440672026-01-012026-03-31in-capmkt:OtherExpenses3Member5440672026-01-012026-03-31in-capmkt:OtherExpenses4Member5440672026-01-012026-03-31in-capmkt:OtherExpenses5Member5440672026-01-012026-03-31in-capmkt:OtherExpenses6Member5440672026-01-012026-03-31in-capmkt:OtherExpenses7Member5440672026-01-012026-03-31in-capmkt:OtherExpenses8Member5440672026-01-012026-03-31in-capmkt:OtherExpenses9Member5440672026-01-012026-03-31in-capmkt:OtherExpenses10Member5440672025-04-012026-03-31in-capmkt:OtherExpenses1Member5440672025-04-012026-03-31in-capmkt:OtherExpenses2Member5440672025-04-012026-03-31in-capmkt:OtherExpenses3Member5440672025-04-012026-03-31in-capmkt:OtherExpenses4Member5440672025-04-012026-03-31in-capmkt:OtherExpenses5Member5440672025-04-012026-03-31in-capmkt:OtherExpenses6Member5440672025-04-012026-03-31in-capmkt:OtherExpenses7Member5440672025-04-012026-03-31in-capmkt:OtherExpenses8Member5440672025-04-012026-03-31in-capmkt:OtherExpenses9Member5440672025-04-012026-03-31in-capmkt:OtherExpenses10Member5440672026-03-31OtherNoncurrentFinancialAssetsDomain15440672026-03-31OtherNoncurrentFinancialAssetsDomain25440672026-03-31OtherNoncurrentAssetsDomain15440672026-03-31OtherNoncurrentAssetsDomain25440672026-03-31OtherCurrentFinancialAssetsDomain15440672026-03-31OtherCurrentFinancialAssetsDomain25440672026-03-31OtherCurrentFinancialAssetsDomain35440672026-03-31OtherCurrentFinancialAssetsDomain45440672026-03-31OtherCurrentFinancialAssetsDomain55440672026-03-31OtherCurrentAssetsDomain15440672026-03-31OtherCurrentAssetsDomain25440672026-03-31OtherCurrentAssetsDomain35440672026-03-31OtherCurrentAssetsDomain45440672026-03-31OtherCurrentAssetsDomain55440672026-03-31OtherCurrentFinancialLiabilitiesDomain15440672026-03-31OtherCurrentFinancialLiabilitiesDomain25440672026-03-31OtherCurrentFinancialLiabilitiesDomain35440672026-03-31OtherCurrentFinancialLiabilitiesDomain45440672026-03-31OtherCurrentFinancialLiabilitiesDomain55440672026-03-31OtherCurrentLiabilitiesDomain15440672026-03-31OtherCurrentLiabilitiesDomain25440672026-03-31OtherCurrentLiabilitiesDomain35440672026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15440672026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25440672025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15440672025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25440672026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares544067INNOVACAPNOTLISTEDINE0DUT01020INNOVA CAPTAB LIMITEDMain BoardEquity2025-04-012026-03-312026-05-072026-04-29INRMillionsQuarterlyFourth quarterSingle segmentDrugs and Pharmaceutical products2026-05-0714:30:002026-05-0715:32:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated4478020000156300004493650000261237000032582000028370000426150000459300001138800004343800003986900000506750000050675000044100000818200001259200000380830000000038083000024400003832700000000572250000106.656.65006.656.651 The above consolidated financial results of Innova Captab Limited the Company or the Holding Company and its subsidiaries Holding and its subsidiaries together referred to as the Group have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards Ind AS notified under Section 133 of the Companies Act 2013 the act read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations 2015 Listing Regulation as amended The results for the quarter and year ended 31 March 2026 are available on the Company website ie www.innovacaptab.com under investor information section and on the stock exchange websites ie www.nseindia.com and www.bseindia.com. <BR> 2 The above consolidated financial results have been reviewed and recommended by Audit Committee at its meeting held on 07 May 2026 The Board of Directors at their meeting held on 07 May 2026 have approved the above results and taken them on record The statutory auditors of the Company have expressed an unmodified opinion on the audited consolidated financial results for the quarter and year ended 31 March 2026 <BR> 3 The Group comprise the following entities all of which have been incorporated in India <BR> Innova Captab Limited Holding Company <BR> Univentis Medicare Limited Wholly owned Subsidary Company <BR> Sharon Bio Medicine Limited Step Down Subsidary Company <BR> Univentis Foundation Subsidiary <BR> 4 The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Codes viz Code on Wages 2019 Code on Social Security 2020 Industrial Relation Code 2020 and Occupational Safety Health and Working Condition Code 2020 collectively referred to as the New Labour Codes These Codes have been made effective from 21 November 2025 The Group has estimated and accounted liability related to gratuity and leave encashment in the financial results and expense for which is included in employee benefits expense The Group continues to monitor developments on the rules to be notified by regulatory authorities including clarifications additional guidance from authorities and will continue to assess the accounting implications basis such developments guidance <BR> 5 The Board of Directors of the Holding Company at their meeting held on 23 January 2026 has approved an interim dividend of Rs 2 per equity share face value Rs 10 per share <BR> 6 The Group has only one reportable segment ie Drugs and pharmaceutical products as per Ind AS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per the listing agreement are not applicable to the group <BR> 7 The figures of the last quarter of the year ended 31 March 2026 and the corresponding quarter ended in the previous year as reported in these consolidated annual financial results are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the financial year Also the figures upto the end of the third quarter had only been reviewed and not subject to audit2025-04-012026-03-31AuditedConsolidated16300180000742000001637438000010054630000583330000-11002000016720400001689800004517900001670990000144917400001882640000018826400002558700002176000004734700000140917000000001409170000406000014132300000000572250000101033567000024.6324.630024.6324.63Power and fuel98180000Packing charges52400000Stores and spares consumed47960000Travelling and conveyance36940000Repairs and maintenance34600000Freight charges51670000Commission on sales32090000Rates, fees and taxes20740000Sales promotion expense21720000Miscellaneous expenses38080000Power and fuel391170000Packing charges196580000Stores and spares consumed192280000Travelling and conveyance133120000Repairs and maintenance131710000Freight charges129950000Commission on sales115230000Rates, fees and taxes65850000Sales promotion expense62330000Miscellaneous expenses2527700008233330000155040000016694000014830000000003940000415870000419810000141700001400600009144180000283256000041285000043728600003199000067000004390000869270000569806000006989900009229610000001837379000057225000010335670000109079200000109079200002158230000000215823000011917000024265000025200500001278670000361440000282489000031863300002804900004745490000125800000395200003501000049458200007465870000183737900001 Property plant and equipment includes amount of right of use of assets <BR> 2 Non current Borrowings include amount of lease liabilitiesSecurity Deposit35090000Balance with banks-deposits accounts with original maturity more than 12 months380780000Capital advances124810000Prepaid expenses15250000Interest accrued but not due on fixed deposits19540000Export incentive recoverable20170000Government grant receivable554030000Balance with banks-deposits accounts with reamining maturity less than 12 months269210000Security deposit6320000Balances with government authorities569750000Advances to suppliers64880000Advances to employees4550000Prepaid expenses33400000Right to return goods26410000Interest accrued but not due on borrowings11310000Employee related payables188970000Capital Creditor - Total outstanding dues of other than micro and small enterprises31330000Unpaid dividend20000Security Deposit48860000Contract liabilities65120000Statutory dues24440000Refund Liability362400001 The Company has only one reportable segment ie Drugs and pharmaceutical products as per Ind AS 108 Operating Segments specified under section 133 of the Companies Act 2013168980000-772910000-10426500000-147990000-142200000-267610000011832700000-533400000451790000-3650000227500000613700000-165300000000000192200000-411520000147112000000-4343000026254000001165150000000000007036000068352000004128500000000000000000000275800000-72770000-10712000000000000033612000027223000001144300001658200000-790000-217150000-1232000000-12320000015519000031990000Remeasurement of defined benefit obligation3190000Income tax relating to items that will not be reclassified to profit or loss-7500002440000Remeasurement of defined benefit obligation5430000Income tax relating to items that will not be reclassified to profit or loss-13700004060000000024400004060000AuditedtrueB S R & Co. LLPtrue2028-07-31